|
Research Interests:
Dr. Shurin's research interest is focused on studies of a therapeutic approaches on incorporation of low-dose chemotherapy into vaccine therapy. The main hypothesis is that low-dose chemotherapeutic agent might modify immunogenecity of the tumor microenvironment and the immunotherapeutic component might then target primary and metastatic tumor and induce specufic antitumor immune memory.
Selected Publications:
Shurin GV, Tourkova IL, Shurin MR. Low-dosechemotherapeutic agents regulate small Rho GTPase activity in dendritic cells. J Immunother. 2008 June; 31(5):491-9.
Zhong H, Han B, Tourkova IL, Lokshin A, Rosenbloom A, Shurin MR, Shurin GV. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res. 2007 September; 13(18):5455-62.
Shurin GV, Tourkova IL, Chatta GS, Schmidt G, Wei S, Djeu JY, Shurin MR. Small Rho GTPases regulate antigen presentation in dendritic cells. J Immunology. 2005 March; 174(6):3394-400.
Shurin GV, Ferris RL, Tourkova IL, Perez L, Lokshin A, Balkir L, Collins B, Chatta GS, Shurin MR. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. 2005 May; 174(9: 5490-8.
|
